NMR-based stable isotope resolved metabolomics was used to characterize small cell neuroendocrine (SCNC) and adenocarcinoma (aCRPC) subtypes of castration-resistant prostate cancer patient-derived xenografts (PDXs). Targeted metabolomics indicated distinct upregulation of metabolic pathways in SCNC relative to aCRPC PDXs. Specifically, [U-13C]glucose and [U-13C]glutamine labeling demonstrated that SCNC PDXs had increased glycolytic rate, alanine aminotransferase and tricarboxylic acid cycle activity, including anaplerotic sources. Further, the metabolic differences observed among the aCRPC and SCNC PDXs exhibited a continuous range as predicted by clinical genomic data of these subtypes of CRPC.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords